NCT00810966: ABT-888 and Cyclophosphamide in Treating Patients With Solid Tumors or Lymphoma That Did Not Respond to Previous Therapy |
|
|
| Active, not recruiting | 1 | 50 | US | cyclophosphamide, veliparib, immunologic technique, laboratory biomarker analysis, liquid chromatography, mass spectrometry, pharmacological study | National Cancer Institute (NCI) | Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific | | | | |
NCT00960050: Methemoglobinemia in Patients With Childhood Hematologic Cancer or Aplastic Anemia Treated With Dapsone |
|
|
| Active, not recruiting | 1 | 173 | US | polymorphism analysis, laboratory biomarker analysis, medical chart review, assessment of therapy complications | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI) | Leukemia, Lymphoma, Methemoglobinemia, Nonmalignant Neoplasm | 05/15 | | | |
NCT00423826: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease |
|
|
| No Longer Available | N/A | | US | Busulfan, Busulfex®, Myleran®, Cytarabine, DepoCyt(TM), Liposomal Ara-C, Fludarabine phosphate, Fludara, mycophenolate mofetil, Cellcept, tacrolimus, Advagraf, Prograf, Protopic, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation | Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI) | Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis | 01/15 | 01/15 | | |